Immunovant Stock Falls After Two Phase 3 Batoclimab Trials Miss Primary Goal
Immunovant's shares dropped sharply in premarket trading after the company announced that both Phase 3 GO trials of batoclimab for active, moderate-to-severe thyroid eye disease failed to achieve the pre-specified primary endpoint. While no new safety concerns emerged, the company noted stronger proptosis improvement during the high-dose period and…